This website is intended for professionals in medicine and healthcare. By selecting “Confirm”, I declare that I am a member of this professional audience. I also agree to the publisher’s rules for using its information resource. Publisher’s resource rules (Russian)
Molecular Medicine
Found: 4
Background. Lung cancer is the most frequent cause of cancer mortality. The prevailing type is non-small cell lung cancer (NSCLC), in the treatment of which EGFR tyrosine kinase inhibitors are actively used, as well as a combination of BRAF and MEK inhibitors.…
Introduction. EGFR mutation and EML4-ALK fusion are the most clinically significant genetic alterations in non-small cell lung cancer. Numerous studies have been devoted to EGFR mutations and their association with phenotypic clinical and pathological characte…
Lung cancer is one of the most common oncologic diseases in the world and the most frequent cause of the death from malignant neoplasms. Last decade’s studies revealed significant number of molecular events leading to the onset and development of non-small cel…
Last successful results in target therapy of cancer were achieved with different tyrosine kinases inhibitors (TKI). Target therapy of non-small cell lung cancer (NSCLC) with EGFR inhibitors gefitinib and erlotinib is effective only in patients with somatic mut…